Top line contracting.
−0.7% YoY versus −2.9% prior. 3y CAGR −1.8%.
−0.7%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $24.4B
Fundamentals as of 2025-12-28
The Question
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
Yes — Illumina, Inc.'s 31.2% ROE ranks above the S&P 500 median, and D/E 1.44 stays within healthy bounds.
Financial story
Yes — Illumina, Inc.'s 31.2% ROE shows strong capital efficiency, and its 1.44 debt-to-equity stays within healthy bounds.
Bottom line: ILMN currently has no legendary investor models qualifying — see /stock/ILMN/valuation for the per-model breakdown, but earns a C sector grade (57/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
−0.7% YoY versus −2.9% prior. 3y CAGR −1.8%.
−0.7%Net margin 19.6% versus −28.0% prior (+47.5pp). Operating 19.9% — gap is tight.
19.6%P/E 29.5x — 39% below the 5y median of 48.3x. Forward 31.0x signals EPS contraction next year.
29.5xHow does ILMN compare?
Illumina, Inc.'s fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
ILMN trades at 23.4x earnings. Sector context and per-investor signals are in the valuation tab.
ILMN and DXCM differ on P/E, ROE, and revenue growth. See the full ILMN vs DXCM compare matrix.
Investor verdicts for ILMN are listed in the valuation tab. Per-model fair value and reasoning are in the valuation tab.
ILMN's P/E ratio is 23.4x. 5-year P/E history is in the financials tab.
Investor verdicts vary by methodology. Full breakdown by investor and signal is in the valuation tab.
See exactly where ILMN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingILMN sits at #27 in Healthcare with a C grade (57/100).